This just to let you know that the FDA has announced the formation of a new level of bureaucracy.
The new task force is charged with determining regulatory approaches that encourage the continued development of innovative, safe and effective FDA-regulated products that use nanotechnology materials.
The task force will identify and recommend ways to address any knowledge or policy gaps that exist so as to better enable the agency to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology materials. FDA will continue to address product-specific nanotechnology-related issues on an ongoing basis.
“As this exciting new area of science develops, FDA must be positioned to address both health promotion and protection challenges that it may present,” said Dr. von Eschenbach. “Through this task force, we are leveraging our expertise and resources to guide the science and technology in the development of nanotechnology-based applications.”